Alphabet investors will be looking for updates on spending, search competition, cloud performance and regulatory news when the Google parent reports earnings Tuesday night. Alphabet is scheduled to ...

Eli Lilly is set to report fourth-quarter earnings early Thursday, with analysts expecting rising sales and profit in the first full quarter with the company's weight-loss drugs no longer in shortage.

What's the most attractive weight-loss stock right now? We asked Seeking Alpha analysts Edmund Ingham, Stephen Ayers and Oneil Trader for their picks. Read more here.

Novo Nordisk NVO is scheduled to report fourth-quarter 2024 results on Feb. 5, 2025, before the opening bell. The Zacks ...

In a report released today, Jo Walton from UBS maintained a Buy rating on Novo Nordisk (0QIU – Research Report), with a price target of ...

Jim Cramer, the host of Mad Money, discussed the upcoming market and corporate activity to look forward to this week, which ...

Major stock indexes closed higher/lower on Friday, after the week saw a flurry of events including DeepSeek scare and ...

The top 20 biopharmaceutical companies experienced mixed performance in 2024 amid a dynamic landscape influenced by various ...

Novo Nordisk A/S investors got a much-needed boost from last week’s trial results for an experimental weight-loss shot. But ...

Weight-loss drugs are transforming health care and Wall Street, but exciting prospects don’t necessarily mean a company is a good investment.

We came across a bullish thesis on Novo Nordisk A/S (NVO) on Long-Term Pick’s Substack by Dan. In this article, we will ...